Search
Research
Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective mannerChemotherapy is included in treatment regimens for many solid cancers, but when administered as a single agent it is rarely curative. The addition of immune checkpoint therapy to standard chemotherapy regimens has improved response rates and increased survival in some cancers. However, most patients do not respond to treatment and immune checkpoint therapy can cause severe side effects. Therefore, there is a need for alternative immunomodulatory drugs that enhance chemotherapy.
Research
Post-surgery financial toxicity and its influencing factors in colorectal cancer care: A cross-sectional studyThis study aimed to investigate the influence factors of financial toxicity experienced by colorectal cancer patients after surgery. The results will provide deep insights for developing effective intervention strategies to address this common issue of colorectal cancer care.
Research
Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma managementTissue-resident memory T (TRM) cells have emerged as key players in the immune control of melanoma. These specialized cells are identified by expression of tissue retention markers such as CD69, CD103 and CD49a with downregulation of egress molecules such as Sphingosine-1-Phosphate Receptor-1 (S1PR1) and the lymphoid homing receptor, CD62L.
News & Events
Childhood cancer research is getting a $1.05 million boost thanks to Australian Lions Childhood Cancer Research FoundationAustralian Lions Childhood Cancer Research Foundation has announced it will provide $1.05 million of funding to The Kids Research Institute Australia.
Research
Prostaglandin E2 imprints a long-lasting effect on dendritic cell progenitors in the bone marrowInjection of BM-differentiated DCs from nonchimeric mice restored the reduced immune responses of PGE2-chimeric mice.
Research
T cells recognizing a 11mer influenza peptide complexed to H-2D b show promiscuity for peptide lengthT-cell repertoire is selected according to self peptide-MHC (major histocompatibility complex) complexes in the thymus.
News & Events
Associate Professor Nick Gottardo awarded Cure Brain Cancer Foundation Innovation Grant 2017The Kids cancer researcher & clinician Dr Nick Gottardo has been announced as the recipient of an Innovation Grant from the Cure Brain Cancer Foundation.
Research
The Immune Response to Skin Trauma Is Dependent on the Etiology of Injury in a Mouse Model of Burn and Excision.This article investigates the impact of burn & excisional injury on the immune system.
Research
Cross-presentation of cutaneous melanoma antigen by migratory XCR1+CD103− and XCR1+CD103+ dendritic cellsThis report provides new insight into the functional specialization within the broad network of dendritic cells that are responsible for skin immunosurveillance
Research
Renal Masses in Childhood: An Australian PerspectiveChildhood renal masses comprise a heterogeneous group of conditions that have a wide range of presentations. This review outlines an approach to the diagnostic work-up of childhood renal masses and discusses the most common presentations and treatments. Renal tumours make up 5% of childhood cancer in Australia, with Wilms tumour being the most common under age 10 years.
Research
Editorial: Insights Into Biomarkers, Cytokines, and Chemokines in Skin CancerOur current Research Topic highlights the complexity of the relationship between the skin, immune system and skin cancer
Research
The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-The KidstherapyHigh medication literacy is the basis of rational medication application and is essential for the management of severe adverse drug reactions. The objective of the present study was to assess the level of medication literacy and determine the association between medication literacy and skin adverse drug reactions in non-small-cell lung cancer (NSCLC) patients undergoing targeted epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-The Kids) therapy.